MetroCream is a U.S. brand name for prescription metronidazole cream 0.75%, formulated for application to the skin in rosacea care. Understanding this exact product matters because metronidazole also appears as vaginal gels, oral tablets and different dermatologic strengths. A brand match requires more than an ingredient name: the route, vehicle, concentration and particular labeled preparation must be correct. The topical metronidazole overview places this product within the broader rosacea formulation family.
MetroCream identifies the emollient 0.75% cream vehicle; it is particularly important to distinguish this brand from Noritate 1% cream. DailyMed records an end date of January 1, 2024 for the Galderma MetroCream branded package (NDC 0299-3836-45). That record documents the named package, not a withdrawal of all metronidazole creams or generic 0.75% products. A pharmacy should identify the currently proposed cream, manufacturer or labeler and approved substitution status; archived carton images do not confirm current brand supply.
This page is a brand-specific reference rather than a second buying hub or an advertisement. It explains the branded cream's labeling, its vehicle, 0.75% strength and regulatory supply context. For the form-specific guide see the metronidazole cream product details; for general access questions see the cream pharmacy access guide. Do not change medication, concentration or application frequency based on a catalogue filter.
MetroCream contains metronidazole at 0.75% in a cream vehicle intended for external skin use. Its labeled context is inflammatory papules and pustules of rosacea; it is not an oral antimicrobial prescription or an intravaginal BV product. Because the drug name crosses very different indications and sites of administration, the pharmacy record must explicitly identify the cream formulation and the skin route. A product whose package does not make those details clear needs clarification.
MetroCream is a brand-level reference for 0.75% cream, not a claim that a cream will work better than a gel in every rosacea presentation. A pharmacist can compare the manufacturer's label, prescribing order and available package identification. A patient should not use a vaginal applicator product on the face or infer that an oral dose is equivalent to a topical amount. The dermatologic product belongs to a distinct treatment plan selected by a healthcare professional.
| Product or listing | Relevant identity | Why it is not interchangeable |
|---|---|---|
| MetroCream | 0.75% topical cream | Exact brand-specific label and route must match |
| Topical metronidazole generic | Formulation and 0.75% must be verified | Generic approval applies to particular strengths and forms |
| Other skin metronidazole forms | 0.75% topical gel, 0.75% lotion and 1% Noritate cream | Cream, gel and lotion have different vehicles and labeling |
| Metronidazole vaginal gel | Intravaginal product for BV | Wrong route even when a similar percentage appears |
The official DailyMed labeling for MetroCream supplies the product name, formulation, ingredients, labeled clinical use, precautions and—where recorded—package identifiers. The label should be the starting point for interpreting any advertised branded medicine. An older document may remain accessible even when a specific marketed package has changed or ended. That is not a contradiction: labeling is a regulatory record, while inventory exists at an individual pharmacy and supplier.
The MetroCream DailyMed label contains a formulation and package description that can be compared with current generic creams; label revision dates and marketing status must be reviewed separately. To assess the current U.S. regulatory context, combine the exact label with FDA approval or marketing information and ask a pharmacist to verify the present-day product being dispensed. Avoid statements such as 'always available' or 'brand guaranteed' merely because a drug database still recognizes the name.
The cream base is more than a texture preference. Its formulation contains inactive ingredients that affect the way a product spreads, dries, feels on the skin and is packaged. Those properties may influence individual tolerability, but they do not establish that one formulation is universally more effective than another. A person experiencing stinging, dryness or another concern should discuss the actual product with the prescriber instead of switching vehicles independently.
The emollient cream base differs from topical gels and lotions in ingredient composition and application feel. Patients sensitive to a particular excipient should review the precise formulation with a clinician or pharmacist instead of interpreting the generic drug name as a complete ingredient list. The treatment plan can also include nonprescription gentle skincare and sun protection as advised for rosacea; neither these measures nor metronidazole itself should be represented as a cure for every form of facial redness. The cream-versus-gel comparison and other formulation guides address these decisions in greater detail.
The label strength is the concentration of metronidazole in the formulation, not a patient-selected dose or a universal equivalence rule. A 0.75% cream cannot be substituted for a product with another concentration or vehicle merely by applying more or less. The prescription should identify the intended product, application instructions and amount to dispense. Where an order is ambiguous, the pharmacist may need to contact the prescriber rather than guessing.
The 0.75% concentration should not be confused with Noritate 1%. Even though both are creams, brand identity and cream base matter when the pharmacy interprets a precise prescription. In particular, metronidazole vaginal gels can also be labeled with percentages, but they have a different route, applicator system and indication. The vaginal versus topical gel comparison is useful when packaging names could be confused.
FDA-approved 0.75% metronidazole cream generics may be available from individual labelers; determine their actual substitution status by approved product and pharmacy review. The FDA Orange Book provides information on approved products and therapeutic-equivalence evaluations, but such information must be checked at the actual form and strength level. A pharmacy's generic offer may come from a different labeler or package than the brand. A shared active ingredient by itself is not proof of approved substitution across forms or concentrations.
MetroCream branding appears in U.S. label records, but archived labeling is not proof that a particular branded carton can be bought today. A generic 0.75% cream does not establish a generic equivalent for Noritate 1% merely because both are metronidazole creams. If the prescribed brand cannot be obtained, ask the pharmacist to check whether the order permits an appropriate approved alternative. Any departure from the intended formulation should be reviewed with the prescriber where required. This brand page does not invent a list of distributors, claim available stock or equate all metronidazole products.
A generic 0.75% metronidazole cream label from Fougera Pharmaceuticals documents an approved topical cream category that is separate from the branded MetroCream record. Its active concentration is described as 7.5 mg per gram. However, an active generic label does not establish that a particular MetroCream branded tube is currently marketed or that every pharmacy has the generic available for immediate dispensing.
Read the brand and generic formulation records separately. The pharmacist should use the actual ordered product and any applicable substitution criteria rather than assuming an ingredient name resolves package or excipient differences. This is especially relevant when a patient has previously experienced irritation with a cream base and needs advice about the supplied ingredients.
MetroCream is a 0.75% emollient cream, whereas Noritate is a 1% cream with micronized metronidazole and a different base. The concentration difference is meaningful for the prescription and product approval, even though both are metronidazole creams for rosacea. The higher figure does not on its own prove greater clinical benefit, nor does it support calculating a smaller amount of cream to replace one prescription with another.
Someone requesting a refill of branded MetroCream should verify whether a 0.75% cream remains on the order. A Noritate entry in the pharmacy search results should be treated as a distinct product requiring proper review, not a synonym. The relevant choice belongs to the clinician and pharmacist after considering the actual disease presentation and prescription.
Topical metronidazole products such as MetroCream are discussed in care for inflammatory rosacea lesions, including papules and pustules. Rosacea can also involve flushing, persistent redness, sensitive skin or other findings that may respond differently to various treatments. The clinician determines the diagnosis and whether this cream is suitable, rather than treating any facial redness as an indication for an antibiotic.
MetroCream 0.75% is a distinct emollient-vehicle product with labeled treatment of inflammatory papules and pustules in rosacea. The original label describes application to affected skin after gentle cleansing and documents local adverse events such as burning, stinging or irritation. Those product-specific details help evaluate a cream prescription but do not establish that a cream is superior to gels or lotions for every patient. A change of formulation should reflect the individual skin response and prescriber judgment.
A prescription for MetroCream 0.75% must be reconciled against a dermal cream, not a vaginal gel, a different topical percentage or a historical brand photograph. The original Galderma-branded NDC carries a marketing end date, while an approved generic 0.75% cream may have its own current record. The dispensing pharmacist should check the appropriate reference and substitution rules before offering a specific generic, and any online pharmacy should verify the prescription rather than provide an unchecked checkout.
When a branded tube is not locally available, the pharmacist can distinguish a prescribed MetroCream formulation from an alternative generic 0.75% cream. The reader should not bypass clinical review by selecting a different concentration. For details of broader prescribing mechanics, see topical metronidazole prescription access. If a brand cannot be ordered, a pharmacist may propose an appropriately approved option rather than declaring that any metronidazole cream, lotion or gel is equivalent.
MetroCream is intended for skin use in the prescribed areas. The product's own label addresses issues such as hypersensitivity, local irritation and avoiding eye contact. Topical systemic exposure is not identical to oral administration, but this is not a reason to ignore the prescribing information or other medicine use. People with reactions or changing symptoms should contact their clinician rather than repeatedly experimenting with different formulations.
For MetroCream, local stinging, burning, erythema or irritation are more useful warning signs to watch than a retail description calling the formula moisturizing. The historical label calls for avoiding contact with the eyes and applying only to the clinician-identified affected skin. If irritation persists or the facial eruption changes, a dermatologist should review the treatment rather than instructing a patient to apply extra cream or switch to a 1% product.
A branded MetroCream tube, a generic 0.75% cream and Noritate 1% should not be grouped into one price average because concentration and product identity differ. A quote for a different concentration, package size or rosacea vehicle is not a valid like-for-like price comparison. Insurance formularies, deductibles, preferred pharmacies and branded versus generic dispensing may affect out-of-pocket costs even when the prescribed active ingredient has not changed.
For comparing 0.75% cream with other dermal formulations, consult topical metronidazole pricing. Request an actual quote for the approved cream that the pharmacist can dispense, including quantity and formulary treatment. An archived MetroCream branded NDC or a 1% Noritate price is not a reliable substitute quote, and a generic option needs product-specific verification.
Before paying or beginning treatment, verify that the label identifies a topical skin cream, metronidazole 0.75%, the correct brand or pharmacist-approved generic, prescribed directions and package. Check whether the drug is actually intended for rosacea rather than BV or another infection, and read any storage or handling instructions supplied with the medicine.
If any item is inconsistent—especially an unfamiliar route, alternate concentration or discontinued branded package—ask the dispensing pharmacist for clarification and prescriber coordination. Check that the package says topical cream and not vaginal cream or topical gel. The aim is a correct and verified medicine, not the fastest possible checkout.
MetroCream is a branded prescription metronidazole cream 0.75% for external skin use in rosacea care.
No. MetroCream is a dermatologic skin product; bacterial vaginosis vaginal products have different formulations and routes.
No. The U.S. MetroCream product is prescription-only.
Approved generic metronidazole cream 0.75% products exist, subject to matching the specific prescription and pharmacy verification.
Not without appropriate pharmacist review and any required prescriber authorization. Exact route, concentration and formulation must be considered.
The product is for topical skin use; label precautions require avoiding the eyes. Follow the prescriber’s directions for appropriate application sites.
No. Oral Flagyl and dermatologic MetroCream have different routes, exposure patterns and clinical purposes.
The Galderma branded package identified as NDC 0299-3836-45 has a recorded marketing end date of January 1, 2024 in DailyMed. That does not mean all approved generic metronidazole 0.75% creams are unavailable. Ask a licensed pharmacy which specific currently dispensable cream, if any, matches the prescription and approved substitution rules.
Product identity, branded versus generic dispensing, package quantity, insurance terms and pharmacy selection may affect cost.
Confirm topical route, 0.75% concentration, cream dosage form, prescription directions, active ingredient and licensed pharmacy dispensing.